Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,939,037
  • Shares Outstanding, K 21,713
  • Annual Sales, $ 0 K
  • Annual Income, $ -373,630 K
  • EBIT $ -530 M
  • EBITDA $ -527 M
  • 60-Month Beta -0.46
  • Price/Sales 434.76
  • Price/Cash Flow N/A
  • Price/Book 6.45

Options Overview Details

View History
  • Implied Volatility 54.57% ( -11.63%)
  • Historical Volatility 83.63%
  • IV Percentile 26%
  • IV Rank 11.39%
  • IV High 156.35% on 02/23/24
  • IV Low 41.48% on 08/19/24
  • Put/Call Vol Ratio 0.94
  • Today's Volume 7,768
  • Volume Avg (30-Day) 960
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 24,309
  • Open Int (30-Day) 23,443

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -5.93
  • Number of Estimates 7
  • High Estimate -4.94
  • Low Estimate -6.28
  • Prior Year -5.68
  • Growth Rate Est. (year over year) -4.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
200.63 +59.29%
on 10/23/24
321.19 -0.50%
on 11/01/24
+110.25 (+52.67%)
since 10/01/24
3-Month
200.63 +59.29%
on 10/23/24
321.19 -0.50%
on 11/01/24
+41.10 (+14.76%)
since 08/01/24
52-Week
133.99 +138.52%
on 11/09/23
321.19 -0.50%
on 11/01/24
+183.09 (+134.14%)
since 11/01/23

Most Recent Stories

More News
Madrigal: Q3 Earnings Snapshot

Madrigal: Q3 Earnings Snapshot

MDGL : 319.58 (+23.23%)
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

MDGL : 319.58 (+23.23%)
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

MDGL : 319.58 (+23.23%)
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

MDGL : 319.58 (+23.23%)
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

MDGL : 319.58 (+23.23%)
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug

Sagimet Biosciences’ SGMT stock rose 12.6% on Tuesday after it announced that the FDA has granted breakthrough therapy designation (“BTD”) to its lead pipeline candidate, denifanstat, for treating...

VKTX : 72.88 (+0.47%)
MDGL : 319.58 (+23.23%)
AKRO : 32.33 (+4.87%)
SGMT : 5.33 (+3.50%)
Is Madrigal Pharmaceuticals Stock a Buy?

The biotech could be worth a lot more in 10 years.

NVO : 111.94 (-0.01%)
LLY : 818.93 (-1.30%)
MDGL : 319.58 (+23.23%)
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock

One player's minor pain is another's moderate gain.

MDGL : 319.58 (+23.23%)
NVO : 111.94 (-0.01%)
Madrigal: Q2 Earnings Snapshot

Madrigal: Q2 Earnings Snapshot

MDGL : 319.58 (+23.23%)
Is It Too Late to Buy Madrigal Pharmaceuticals Stock?

Will being the first to its market ensure that its future is bright?

MDGL : 319.58 (+23.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 397.90
2nd Resistance Point 359.55
1st Resistance Point 339.56
Last Price 319.58
1st Support Level 281.22
2nd Support Level 242.87
3rd Support Level 222.88

See More

52-Week High 321.19
Last Price 319.58
Fibonacci 61.8% 249.68
Fibonacci 50% 227.59
Fibonacci 38.2% 205.50
52-Week Low 133.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar